Subscribe To

Price Alert Latest News Economic Calendar News

IPA / IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022

VICTORIA, British Columbia--( BUSINESS WIRE )--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2023, on Thursday, December 15, 2022, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. Read More

Demo Live Account See Partner Details

Content Topics

Report

Financial

Results

Recent

Business

Highlights

Second

Quarter

Fiscal

December

Stock

IPA

Posted: Dec 5 2022, 08:04

Author Name: Business Wire

IPA News

By Zacks Investment Research
March 16, 2023

ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates

ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of -16.67% and 6.19%, respectively, for the quarter ended January 2023.

By Business Wire
March 7, 2023

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023 on March 16, 2023

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advan

By Seeking Alpha
December 15, 2022

ImmunoPrecise Antibodies Ltd. (IPA) Q2 2023 Earnings Call Transcript

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q2 2023 Earnings Conference Call December 15, 2022 10:30 AM ET Company Participants Jennifer Bath – Chie

By Business Wire
December 5, 2022

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2023 on December 15, 2022

VICTORIA, British Columbia--( BUSINESS WIRE )--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an advanced biother

By Business Wire
July 26, 2022

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IP

By Seeking Alpha
March 16, 2022

ImmunoPrecise Antibodies Ltd. (IPA) CEO Jennifer Bath on Q3 2022 Results - Earnings Call Transcript

By Business Wire
March 8, 2022

ImmunoPrecise Sets Third Quarter Fiscal 2022 Financial Results and Recent Business Highlights Conference Call for Wednesday, March 16th at 10:30 a.m. ET

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE:

By Benzinga
January 31, 2022

ImmunoPrecise's COVID-19 Antibody Cocktail Shows Neutralization Activity Against Omicron

Immunoprecise Antibodies Ltd IPA has released preclinical data for the PolyTope TATX-03 COVID-19 antibody cocktail. [ALERT] Nic Chahine shares his Be

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.